Capital Asset Advisory Services LLC Purchases Shares of 1,088 Novartis AG (NYSE:NVS)


Share on StockTwits

Capital Asset Advisory Services LLC purchased a new stake in Novartis AG (NYSE:NVS) during the 4th quarter, HoldingsChannel reports. The fund purchased 1,088 shares of the company’s stock, valued at approximately $103,000.

Several other large investors have also added to or reduced their stakes in the business. Fisher Asset Management LLC raised its holdings in shares of Novartis by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 9,337,800 shares of the company’s stock valued at $881,768,000 after acquiring an additional 273,520 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Novartis by 0.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,669,601 shares of the company’s stock valued at $440,950,000 after acquiring an additional 29,894 shares in the last quarter. Morgan Stanley raised its holdings in shares of Novartis by 10.3% in the 4th quarter. Morgan Stanley now owns 2,808,993 shares of the company’s stock valued at $265,253,000 after acquiring an additional 263,445 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Novartis by 2.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,796,311 shares of the company’s stock valued at $264,056,000 after acquiring an additional 64,713 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Novartis by 8.6% in the 4th quarter. Principal Financial Group Inc. now owns 1,674,186 shares of the company’s stock valued at $158,093,000 after acquiring an additional 132,070 shares in the last quarter. 9.86% of the stock is currently owned by hedge funds and other institutional investors.

NVS opened at $86.30 on Thursday. The stock’s 50 day simple moving average is $86.31 and its 200 day simple moving average is $88.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 0.91 and a quick ratio of 0.69. Novartis AG has a 1 year low of $77.04 and a 1 year high of $98.52. The firm has a market cap of $197.51 billion, a price-to-earnings ratio of 27.93, a PEG ratio of 1.76 and a beta of 0.59.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Monday, January 25th. The company reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.03). Novartis had a return on equity of 24.39% and a net margin of 14.71%. The company had revenue of $12.77 billion for the quarter, compared to the consensus estimate of $12.86 billion. During the same quarter in the previous year, the business earned $1.32 earnings per share. Novartis’s revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Novartis AG will post 5.8 EPS for the current year.

The business also recently declared an annual dividend, which was paid on Monday, March 15th. Investors of record on Friday, March 5th were given a dividend of $3.3784 per share. This represents a yield of 2.2%. This is a positive change from Novartis’s previous annual dividend of $3.04. The ex-dividend date was Thursday, March 4th. Novartis’s dividend payout ratio (DPR) is presently 39.69%.

A number of equities analysts recently weighed in on the company. Morgan Stanley reissued an “overweight” rating on shares of Novartis in a report on Tuesday, February 2nd. Cowen cut Novartis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $110.00 to $105.00 in a report on Monday, February 1st. Societe Generale reissued a “buy” rating on shares of Novartis in a report on Tuesday, March 23rd. Argus reissued a “hold” rating on shares of Novartis in a report on Tuesday, March 16th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Novartis in a report on Friday, January 15th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $108.50.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

Read More: Dollar Cost Averaging

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.